PRI Health Care Alert

View this email in your browser ([link removed])
[link removed]
Vance's Argument on Pre-Existing Conditions is a Sure Winner
Newsmax | October 8 2024 | Sally C. Pipes

When asked how people with pre-existing conditions would fare under a Trump-Vance administration during last week’s vice-presidential debate, Sen. J.D. Vance, R-Ohio, was unequivocal. “Well, of course, we’re going to cover Americans with pre-existing conditions.”

The question was prompted by Vance’s statement last month that the Republican ticket would consider creating different risk pools for chronically ill people in order to expand the number of insurance choices available to all Americans — rather than the one-size-fits-all status quo under Obamacare.

Democrats seized on the comment, arguing that Republicans wanted to “rip away” protections for those with pre-existing conditions.

But that just isn’t the case.
Read here . . . ([link removed])
How the Hospital Industrial Complex Robs Poor Patients
Forbes | Sally Pipes | October 7, 2024

Pharmaceutical leader Johnson & Johnson recently unleashed a firestorm in Washington after it proposed a change to how it offers discounted prices on two drugs in a little-known, but enormous, federal program that’s hurting the low-income patients it was created to help.

That program, known as the “340B Drug Pricing Program,” allows certain hospitals—and their affiliated clinics and pharmacies—to access medicines at significantly lower prices offered by pharmaceutical manufacturers.

To help ensure that 340B discounts are being obtained lawfully and benefit the low-income patients they’re intended for, J&J proposed offering such discounts as retroactive rebates—rather than upfront discounts—for a subset of 340B hospitals on two of its medicines. This change was intended to help bring much-needed transparency to the 340B program.
Read more... ([link removed])

------------------------------------------------------------

Watch PRI's Webinar: The Biosimilar Promise: How Biosimilars Reform Could Save Patients and Taxpayers Even More
Pacific Research Institute | October 9, 2024

Low-cost biosimilars generated $19 billion in savings value in today’s dollars in 2023. But obstacles in the current drug pricing system meant that billions of dollars in potential savings were left unrealized. Join the Pacific Research Institute’s Center for Medical Economics and Innovation and panel of experts for a brief, informative webinar discussing how potential reforms can improve competition, generate more savings, and better serve patients and taxpayers.

Watch here... ([link removed])

[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.